KR20240110816A - 실로사이빈을 이용한 치료 저항성 우울증의 치료 - Google Patents

실로사이빈을 이용한 치료 저항성 우울증의 치료 Download PDF

Info

Publication number
KR20240110816A
KR20240110816A KR1020247017950A KR20247017950A KR20240110816A KR 20240110816 A KR20240110816 A KR 20240110816A KR 1020247017950 A KR1020247017950 A KR 1020247017950A KR 20247017950 A KR20247017950 A KR 20247017950A KR 20240110816 A KR20240110816 A KR 20240110816A
Authority
KR
South Korea
Prior art keywords
psilocybin
dose
subject
weeks
depression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247017950A
Other languages
English (en)
Korean (ko)
Inventor
트레버 앤서니 밀
가이 매닝 굿윈
조이스 차이
린지 마우드
선일 미스트리
Original Assignee
컴퍼스 패쓰파인더 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 컴퍼스 패쓰파인더 리미티드 filed Critical 컴퍼스 패쓰파인더 리미티드
Publication of KR20240110816A publication Critical patent/KR20240110816A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020247017950A 2021-11-09 2022-11-02 실로사이빈을 이용한 치료 저항성 우울증의 치료 Pending KR20240110816A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163277407P 2021-11-09 2021-11-09
US63/277,407 2021-11-09
US202163284973P 2021-12-01 2021-12-01
US63/284,973 2021-12-01
PCT/US2022/048713 WO2023086252A1 (en) 2021-11-09 2022-11-02 Treatment of treatment resistant depression with psilocybin

Publications (1)

Publication Number Publication Date
KR20240110816A true KR20240110816A (ko) 2024-07-16

Family

ID=84799979

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247017950A Pending KR20240110816A (ko) 2021-11-09 2022-11-02 실로사이빈을 이용한 치료 저항성 우울증의 치료

Country Status (8)

Country Link
US (1) US20250000881A1 (cg-RX-API-DMAC10.html)
EP (1) EP4429671A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024543379A (cg-RX-API-DMAC10.html)
KR (1) KR20240110816A (cg-RX-API-DMAC10.html)
AU (1) AU2022387053A1 (cg-RX-API-DMAC10.html)
CA (1) CA3237885A1 (cg-RX-API-DMAC10.html)
MX (1) MX2024005632A (cg-RX-API-DMAC10.html)
WO (1) WO2023086252A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
MX2023011326A (es) * 2021-03-30 2023-10-03 Compass Pathfinder Ltd Composiciones de psilocibina, metodos para prepararlas y metodos de uso de estas.
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2588505B (en) * 2017-10-09 2022-08-03 Compass Pathfinder Ltd Preparation of psilocybin
GB2571696B (en) * 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20220008824A (ko) * 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
MX2023011326A (es) * 2021-03-30 2023-10-03 Compass Pathfinder Ltd Composiciones de psilocibina, metodos para prepararlas y metodos de uso de estas.

Also Published As

Publication number Publication date
EP4429671A1 (en) 2024-09-18
JP2024543379A (ja) 2024-11-21
MX2024005632A (es) 2024-07-29
WO2023086252A1 (en) 2023-05-19
US20250000881A1 (en) 2025-01-02
AU2022387053A1 (en) 2024-05-09
CA3237885A1 (en) 2023-05-19

Similar Documents

Publication Publication Date Title
AU2020259406B2 (en) Treatment of depression and other various disorders with psilocybin
US20250000881A1 (en) Treatment of treatment resistant depression with psilocybin
KR20240122455A (ko) 치료-저항성 우울증의 치료에서 사용하기 위한 실로사이빈 및 보조적 세로토닌 재흡수 저해제
TW201242600A (en) Treatment of cognitive dysfunction in schizophrenia
CN118488843A (zh) 用赛洛西宾治疗难治性抑郁症
HK40068334A (en) Treatment of depression and other various disorders with psilocybin
HK40068314A (en) Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000